Sign In
Buy XCUR
$2.73
-0.0100 (-0.365%)
At Close: Jun 23, 2026
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes.
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results.
Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
04:01pm, Wednesday, 18'th Sep 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today that on September 17, 2024, the Company received notice that the Nasdaq Hearings Panel (“
Exicure, Inc. Announces 1-for-5 Reverse Stock Split
09:08am, Monday, 26'th Aug 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse St
Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
04:27pm, Thursday, 08'th Aug 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics.
Exicure, Inc. Receives Positive Listing Determination from Nasdaq
04:01pm, Thursday, 01'st Aug 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Receives Positive Listing Determination from Nasdaq.
Why Is Exicure (XCUR) Stock Down 27% Today?
08:37am, Monday, 22'nd Jul 2024
Exicure (NASDAQ: XCUR ) stock is dropping on Monday after the prior early-stage pharmaceutical company's shares underwent a rally on Friday. That rally resulted in shares of XCUR stock rising 76% hig
Exicure, Inc. Reports First Quarter 2024 Financial Results
04:01pm, Monday, 17'th Jun 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, the “Company”), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic
Exicure, Inc. Reports Full Year 2023 Financial Results
04:01pm, Thursday, 06'th Jun 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. Reports Full Year 2023 Financial Results.
Exicure, Inc. Received Nasdaq Notice of a Delisting Determination
04:01pm, Thursday, 23'rd May 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received notice of a delisting determination (the “Staff Delisting Determination”) f
Exicure, Inc. Reports Third Quarter 2023 Financial Results
04:08pm, Thursday, 16'th May 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against valid
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
04:01pm, Monday, 22'nd Apr 2024
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (“Exicure” or the “Company”) (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on April
CHICAGO--(BUSINESS WIRE)--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company
Why Is Exicure (XCUR) Stock Up 57% Today?
08:40am, Friday, 08'th Dec 2023
Exicure (NASDAQ: XCUR ) stock is rising higher on Friday despite a lack of news from the early-stage biotechnology company. Exicure hasn't released any recent press releases or made any filings that
